HDM-2024

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameHDM-2024
Drug Alias NameHDM2024HDM-2024
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-Receptor tyrosine-protein kinase erbB-3
TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuadong Medicine Co LtdHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A